Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-10-21Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMTJAMA Network Open · 2026-09-29Psilocybin in the Treatment of Methamphetamine Use DisorderClinicalTrials.gov · 2026-09-21Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01Differential effects of psilocybin derivatives on fentanyl-induced conditioned place preference in male and female mice.Journal of psychopharmacology (Oxford, England) · 2026-08-30A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord InjuryClinicalTrials.gov · 2026-08-10Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentBiomolecules · 2026-07-03The Australia story: Current status and future challenges for the clinical applications of psychedelics.British journal of pharmacology · 2026-07-01Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentUniversity of Groningen research database (University of Groningen / Centre for Information Technology) · 2026-06-29Psychedelics relax predictive processing in the post-acute period by remodeling cortico-cortical feedback circuits.bioRxiv: the preprint server for biology · 2026-06-15Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headacheJournal of Psychopharmacology · 2026-05-29Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.PsyArXiv · 2026-05-14Psilocybin in the Treatment of Cocaine Use DisorderJAMA Network Open · 2026-05-07A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experienceFrontiers in Public Health · 2026-04-14Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysisNeuroscience & Biobehavioral Reviews · 2026-04-01PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial.Palliative medicine · 2026-04-01Psilocybin or Nicotine Patch for Smoking CessationJAMA Network Open · 2026-03-10Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase).Psychiatry research · 2026-03-01Psychedelic therapy and cultural humility.Translational psychiatry · 2026-02-27Patient perspectives on research gaps in cluster headache.Headache · 2026-02-01Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 StudyPsychedelic Medicine · 2026-01-18An open-label pilot study of psilocybin-assisted therapy for binge eating disorder.Journal of eating disorders · 2026-01-03Additional file 1 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorderFigshare · 2026-01-01Additional file 2 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorderFigshare · 2026-01-01Towards "unmakable" psychedelics: SAR exploration of psilocin analogs obtained by a HATU-mediated amide coupling strategyEuropean Journal of Medicinal Chemistry Reports · 2025-12-01Sex-specific role of the 5-HT receptor in psilocybin-induced extinction of opioid reward.Nature communications · 2025-11-20Salience, sensemaking, and setting in psilocybin microdosingRepository of the University of Ljubljana (University of Ljubljana) · 2025-11-18Five-year outcomes of psilocybin-assisted therapy for Major Depressive DisorderJournal of Psychedelic Studies · 2025-09-04551. PSYCHEDELICS AND OCD: TRANSLATIONAL APPROACHESThe International Journal of Neuropsychopharmacology · 2025-07-31Intravenous psilocybin induces dose-dependent changes in functional network organization in rat cortex.Translational psychiatry · 2025-03-25Further education in psychedelic-assisted therapy - experiences from Switzerland.BMC medical education · 2025-03-05A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.Psychedelic medicine (New Rochelle, N.Y.) · 2025-03-01Psilocybin mushroom stewardship: A qualitative inquiry into practices and priorities of “underground” psilocybin mushroom practitionersJournal of Psychedelic Studies · 2025-02-05Psychedelic Microdosing among Young Adults from Southern California.Journal of psychoactive drugs · 2025-01-01Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine.Journal of psychoactive drugs · 2025-01-01Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program.Neuroscience applied · 2025-01-01Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024-12-02New frontiers in the biosynthesis of psychoactive specialized metabolites.Current opinion in plant biology · 2024-12-01Amid magic and menace: psychiatrists' attitudes to psilocybin therapy.Irish journal of psychological medicine · 2024-11-07The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelicsPsyArXiv · 2024-10-22Salience, sensemaking, and setting in psilocybin microdosing: Methodological lessons and preliminary findings of a mixed method qualitative studyPhilosophical Psychology · 2024-09-26Psilocybin-assisted therapy and HIV-related shame.Scientific reports · 2024-08-02Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney's lesions.European archives of psychiatry and clinical neuroscience · 2024-06-01Psychedelika-assistierte PsychotherapieDie Psychotherapie · 2024-02-28Effects of psilocybin and sleep quality on brain water diffusivity and microstructure in healthy individuals and chronic cluster headache patientsNeuroscience Applied · 2024-01-01Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.The American journal of psychiatry · 2024-01-01CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity.Headache · 2024-01-01Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain.Current biology: CB · 2023-12-18A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic aminesJournal of Biological Chemistry · 2023-09-09Psilocybin intoxication did not affect daytime or sleep-related declarative memory consolidation in a small sample exploratory analysis.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2023-09-01Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.Neuropharmacology · 2023-08-01Introduction to the chemistry and pharmacology of psychedelic drugsAustralian Journal of Chemistry · 2023-07-04A review of psilocybin: chemistry, clinical uses and future research directionsAustralian Journal of Chemistry · 2023-05-16Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.EClinicalMedicine · 2023-02-01Going on Trial: Serotonin drug; psilocybin phase 2; placebo response dataThe Transmitter · 2023-01-01Company on brink takes psilocybin to trial for fragile X syndromeThe Transmitter · 2023-01-01Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdosesThe Transmitter · 2023-01-01Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom useDrug Science Policy and Law · 2023-01-01Adapting psychedelic medicine for headache and chronic pain disorders.Expert review of neurotherapeutics · 2023-01-01Biological studies of clavine alkaloids targeting CNS receptors.Frontiers in psychiatry · 2023-01-01Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.The New England journal of medicine · 2022-11-03Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.Neuropharmacology · 2022-11-01Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.Current psychiatry reports · 2022-10-01Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations.Neuropharmacology · 2022-08-15Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivitymedRxiv · 2022-07-10Psilocybin-Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience.Journal of personalized medicine · 2022-06-19Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer.Current treatment options in oncology · 2022-03-01Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.Journal of psychopharmacology (Oxford, England) · 2022-01-01Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report.Frontiers in pharmacology · 2022-01-01A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive EffectsPsyArXiv · 2021-12-14Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses-A Simultaneous EEG-FMRI Study.Cerebral cortex (New York, N.Y.: 1991) · 2021-11-23Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.Translational psychiatry · 2021-11-08Spontaneous and deliberate creative cognition during and after psilocybin exposure.Translational psychiatry · 2021-04-08How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and TranscendenceAnesthesia & Analgesia · 2021-02-17Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research.Frontiers in psychiatry · 2021-01-01The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant ActionInstitutional Repositories DataBase (IRDB) · 2020-12-03Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2020-11-01Psilocybin-assisted group therapy: A new hope for demoralization.EClinicalMedicine · 2020-10-01Dynamic coupling of whole-brain neuronal and neurotransmitter systems.Proceedings of the National Academy of Sciences of the United States of America · 2020-04-28The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action.Frontiers in pharmacology · 2020-01-01Accounting for Microdosing Classic PsychedelicsJournal of Drug Issues · 2019-08-30The ethics of psychedelic research in disorders of consciousness.Neuroscience of consciousness · 2019-01-01Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.Frontiers in psychiatry · 2019-01-01The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.Neuropharmacology · 2018-11-01Facile assembly and fluorescence-based screening method for heterologous expression of biosynthetic pathways in fungi.Metabolic engineering · 2018-07-01The relationships of classic psychedelic use with criminal behavior in the United States adult population.Journal of psychopharmacology (Oxford, England) · 2018-01-01Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study.Frontiers in psychology · 2018-01-01Psilocybin and palliative end-of-life care.Journal of psychopharmacology (Oxford, England) · 2016-12-01Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans.The international journal of neuropsychopharmacology · 2016-07-01A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State.Journal of analytical toxicology · 2015-10-01Psilocybin, psychological distress, and suicidality.Journal of psychopharmacology (Oxford, England) · 2015-09-01Homological scaffolds of brain functional networks.Journal of the Royal Society, Interface · 2014-12-06The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs.Frontiers in human neuroscience · 2014-01-01Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.Scandinavian journal of clinical and laboratory investigation · 2013-08-01Anticholinergic toxicity after the ingestion of serotonergic 'magic mushrooms'Netherlands Journal of Critical Care · 2012-06-01Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.The British journal of psychiatry: the journal of mental science · 2012-03-01Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.Proceedings of the National Academy of Sciences of the United States of America · 2012-02-07Unifying electron transfer mechanism for psilocybin and psilocinMedical Hypotheses · 2009-10-01Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials.Clinical toxicology (Philadelphia, Pa.) · 2009-07-01Novel, unifying mechanism for mescaline in the central nervous system: electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships.Oxidative medicine and cellular longevity · 2009-01-01Detection and determination of abused hallucinogens in biological material.Neuro endocrinology letters · 2006-12-01Determination of psilocin and psilocybin using flow injection analysis with acidic potassium permanganate and tris(2,2′-bipyridyl)ruthenium(II) chemiluminescence detection respectivelyTalanta · 2005-08-15Preparation of the 4-Hydroxytryptamine Scaffold via Palladium-Catalyzed Cyclization: A Practical and Versatile Synthesis of PsilocinOrganic Letters · 2003-03-01What geometric visual hallucinations tell us about the visual cortex.Neural computation · 2002-03-01Synthesis of Baeocystin, a natural Psilocybin AnalogueArchiv der Pharmazie · 1988-01-01The danger of hallucinogenic mushrooms.Scottish medical journal · 1979-10-01A characteristic effect of hallucinogens on investigatory responding in rats.Psychopharmacology · 1979-09-01The effects of lysergic acid diethylamide and mescaline-derived hallucinogens on sensory-integrative function: tactile startle.The Journal of pharmacology and experimental therapeutics · 1978-12-01ChemInform Abstract: CRYSTAL STRUCTURES OF THE TEONANACATL HALLUCINOGENS PART1, PSILOCYBIN C12H17N2O4OChemInform · 1974-09-03ChemInform Abstract: CRYSTAL STRUCTURES OF THE TEONANACATL HALLUCINOGENS PART2, PSILOCIN C12H15N2OChemischer Informationsdienst · 1974-09-03Crystal structures of the Teonanácatl hallucinogens. Part I. Psilocybin C12 H17 N2 O4 PJournal of the Chemical Society Perkin Transactions 2 · 1974-01-01Crystal structures of the Teonanácatl hallucinogens. Part II. Psilocin, C12 H15 N2 OJ. Chem. Soc., Perkin Trans. 2 · 1974-01-01Molecular structures of hallucinogenic substances: lysergic acid diethylamide, psilocybin, and 2,4,5-trimethoxyamphetamine.Molecular pharmacology · 1973-01-01Hypnotic Induction of the Interference of Psilocybin with Optically Induced Spatial DistortionPharmacopsychiatry · 1969-11-01Occurrence of psilocybin in the sporophores of Psilocybe semilanceataTransactions of the British Mycological Society · 1969-10-01Structure-activity relationships among 5-methoxy-n:n-dimethyltryptamine, 4-hydroxy-n:n-dimethyltryptamine (psilocin) and other substituted tryptamines.Life sciences · 1968-03-01Changes in spider webs brought about by mescaline, psilocybin and an increase in body weight.The Journal of pharmacology and experimental therapeutics · 1962-04-01The relationship between the metabolic fate and pharmacological actions of serotonin, bufotenine and psilocybin.The Journal of pharmacology and experimental therapeutics · 1960-10-01